Exact Mass: 475.1159
Exact Mass Matches: 475.1159
Found 82 metabolites which its exact mass value is equals to given mass value 475.1159,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
E3040 glucuronide
A member of the class of benzothiazoles that is E3040 in which the hydroxy hydrogen at position 6 has been replaced by a beta-D-glucosiduronic acid group. It is a metabolite of the anti-inflammatory drug, E3040.
Ertapenem
Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Ertapenem
Ertapenem is only found in individuals that have used or taken this drug. It is a carbapenem antibiotic marketed by Merck as Invanz®. It is structurally very similar to meropenem in that it possess a 1-beta-methyl group. [Wikipedia]The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
TS-943
[(2R,5R)-5-(6-Aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 2-benzoylbenzoate
Cys Cys His Asn
Cys Cys Asn His
Cys His Cys Asn
Cys His Asn Cys
Cys Asn Cys His
Cys Asn His Cys
His Cys Cys Asn
His Cys Asn Cys
His Asn Cys Cys
Asn Cys Cys His
Asn Cys His Cys
Asn His Cys Cys
TERT-BUTYL 4-(4-(2-BROMOBENZYL)PIPERAZIN-1-YL)-3-NITROBENZOATE
2-[ethyl[4-[(6-nitrobenzothiazol-2-yl)azo]phenyl]amino]ethyl benzoate
Phenyl N-Benzyl-2-amino-4,6-O-benzylidene-2-N,3-O-carbonyl-2-deoxy-1-thio-beta-D-glucopyranoside
[(2R,5R)-5-(6-Aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 2-benzoylbenzoate
N-[4-(1,3-benzoxazol-2-yl)phenyl]-4-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-methanoisoindol-2-yl)benzamide
3-L-lysyl-AMP
An L-lysyl ester obtained by formal condensation of the carboxy group of L-lysine with the 3-hydroxy group of AMP.
3-L-glutaminyl-AMP
An L-glutaminyl derivative that is the ester obtained by formal condensation of the carboxy group of L-glutamine with the 3-hydroxy group of AMP.
N(6)-(5-adenylyl)-L-lysine
An L-lysine derivative that is the phosphoramidate obtained by formal condensation of the phosphate group of AMP with the side-chain amino group of L-lysine.
2-[(7-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinolin-1-yl)thio]-N-methyl-N-(4-phenyl-2-thiazolyl)acetamide
2-O-acetylbulbisine Trifluoroacetic acid
A natural product found in Crinum asiaticum var. sinicum.
1-O-acetylbulbisine Trifluoroacetic acid
A natural product found in Crinum asiaticum var. sinicum.
N-[5-(4-morpholinylsulfonyl)-2-(1-pyrrolidinyl)phenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide
4-[(3aR,4S,9bR)-4-(hydroxymethyl)-1-(2-methoxyphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
(3R)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester
4-[(3aR,4R,9bR)-4-(hydroxymethyl)-1-(2-methoxyphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
[(1S)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,3S,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,3S,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
(3S)-4-(3-bromophenyl)-3-(2-hydroxyethyl)-2-[oxo-(propan-2-ylamino)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid ethyl ester
4-[(3aS,4S,9bS)-4-(hydroxymethyl)-1-(2-methoxyphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
4-[(3aS,4R,9bS)-4-(hydroxymethyl)-1-(2-methoxyphenyl)sulfonyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
[(1R)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
Buloxibutid
Buloxibutid (AT2 receptor agonist C21) is a agentlike selective angiotensin II AT2 receptor agonist with Ki values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively[1].
KCC009
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
